- Many U.S. adults with high LDL-C are not receiving recommended therapy.
- Study analyzed data from nearly 5,000 adults (NHANES 2013-2020).
- Full guideline adherence could reduce cardiovascular events by 21-27%.
- Potential annual savings of $25-$32 billion in healthcare costs.
- Low usage noted for non-statin therapies such as xyz.
- 47-88% of adults were eligible for cholesterol treatment.
- The 2019 EU guideline targets showed the greatest benefits.
- The study signals the need for better implementation of cholesterol management strategies.
Source: Springer Nature Link